cancer risk of anti-tnf-α at recommended doses in adult rheumatoid arthritis a meta-analysis with intention to treat and per protocol analyses癌症的风险在推荐剂量anti-tnf-α成人类风湿性关节炎与意图治疗分析和协议分析.pdfVIP

Cancer Risk of Anti-TNF-a at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses 1,2,3,4 ` 2,3,4 ´ ´ 5,6 2,3,4 1,3,4 Guillaume Moulis *, Agnes Sommet , Johana Bene , Franc¸ois Montastruc , Laurent Sailler , Jean-Louis Montastruc2,3,4, Maryse Lapeyre-Mestre2,3,4 ´ ´ ´ 1 CHU Toulouse, Service de Medecine Interne, Toulouse, France, 2 CHU Toulouse, Service de Pharmacologie Clinique, Centre Midi-Pyrenees de PharmacoVigilance, de ´ ´ ´ ´ Pharmacoepidemiologie et d’Informations sur le Medicament, Toulouse, France, 3 Inserm, UMR1027, Toulouse, France, 4 Universite de Toulouse III, UMR1027, Toulouse, ´ France, 5 CHU Lille, Centre Nord-Pas de Calais de PharmacoVigilance, Lille, France, 6 Universite de Lille II, Lille, France Abstract Background: The risk of malignancies on TNF-a antagonists is controversial. The aim of this survey was to assess cancer risk on TNF-a antagonists in adult rheumatoid arthritis patients, including the five marketed drugs (infliximab, etanercept, adalimumab, golimumab and certolizumab) used in line with the New Drug Application. Furthermore, the relative interest of modified intention to treat or per protocol analyses to assess such sparse events remains unknown. Methodology/Principal Findings: Data sources were MEDLINE, CENTRAL, ISI Web of Science